AstraZeneca’s chief executive said the U.K.’s “discouraging” tax rate was behind the company’s decision to build a $400 million API facility at the former Alexion campus in Dublin. Speaking to ...
NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results